Macrogen
Company type | Public |
---|---|
KRX: 038290 | |
Founded | 1997 |
Founder | Jeong-sun Seo |
Headquarters | , South Korea |
Area served | global |
Key people | Hyon-yong Chong (CEO, 2015) |
Products |
|
Divisions |
|
Website | www |
Macrogen, Inc. is a South Korea public biotechnology company.[1] The company's headquarters are located in Seoul.[2] The company was founded in 1997 by Jeong-sun Seo,[note 1] a professor at Seoul National University.[3] It was venture capital-backed until its initial public offering (IPO) and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO.[1][3] The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed.[4] By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine".[5]
Business model
Macrogen's business model focuses on providing research services to other firms engaged in biotechnology research and development.[3] As of 2005[update], 50% of the firm's revenue was derived from DNA sequencing services.[3] Prior to its 2000 IPO, the company aimed to be the low-cost leader in providing research services; after the IPO, Macrogen turned to DNA sequencing technology development as a way to distinguish itself from competitors.[3] As of 2015[update], the company had four main divisions based on geography: Korea, USA, Europe and Japan.[6]
Consistent with the post-IPO competitive technology strategy was Macrogen's being among the first customers to purchase a HiSeq X Ten System from Illumina in January 2014,[7] purported to be the first sequencing system to enable cracking the $1,000 genome boundary.[8]
In 2015, the company underwent a corporate identity revision, which included a revised corporate logo and a revised corporate slogan: "Humanizing Genomics."[5]
Corporate governance
As of 2014, HyungTae Kim held the role of chief executive officer (CEO) at Macrogen.[2] By early 2015, however, the CEO role had been filled by Hyon-yong Chong.[5]
With respect to the company's Board, founder Jeong-sun Seo remained Chairman as of 2015.[5]
According to KOSDAQ statistics, over 90% of the company's outstanding stock is held by individual investors.[9]
Strategic and tactical relationships
In late 2014, Macrogen licensed Clarity LIMS from GenoLogics, a system "built specifically for the needs of clinical or research genomics and mass spec laboratories".[7] Initial integration with service offerings was to be through the USA-based Macrogen Clinical Laboratory.[7]
In 2014 and 2015, Macrogen won competitive bidding rounds to provide genome analysis services to the University College London.[10]
Macrogen Corp
References
- ^ a b "(unknown)". Korea Now. 31. 2002. ISBN 978-2916914534. Retrieved 2015-07-14 – via Google Books (snippet view).
{{cite journal}}
: Cite uses generic title (help) - ^ a b Staff (November 3, 2014). "Macrogen Introduces Latest Service Portfolio and Presents Research Outcome at 2014 ASHG Annual Meeting". Biotech Business Week. Retrieved 2015-07-15 – via HighBeam Research.
- ^ a b c d e Wong, Joseph (September 15, 2011). Betting on Biotech: Innovation and the Limits of Asia's Developmental State. Cornell University Press. pp. 97–8. ISBN 0801463386 – via Google Books (preview).
- ^ Sleeboom-Faulkner, Margaret (2010). Frameworks of Choice: Predictive & Genetic Testing in Asia. Amsterdam University Press. p. 28. ISBN 9789089641656 – via Google Books (full view).
- ^ a b c d Staff (April 15, 2015). "Macrogen Renews CI after 19 Years, Making a Great Leap Forward to Be a Global Leader of Personalized Genomic Medicine". Biotech Week. Retrieved 2015-07-15 – via HighBeam Research.
- ^ "Macrogen". www.macrogen.com. See footer content. Retrieved 2015-07-15.[self-published source]
- ^ a b c Staff (November 4, 2014). "Macrogen Selects GenoLogics' Clarity LIMS to Strengthen X-Genome and Clinical Sequencing Services". Information Technology Newsweekly. Retrieved 2015-07-15 – via HighBeam Research.
- ^ "Illumina Introduces the HiSeq X™ Ten Sequencing System" (Press release). Illumina. January 14, 2014. Retrieved 2015-07-15.
- ^ "Trading Performance by Investor". KRX Korea Exchange. Korea Exchange. Sort table by percent. Retrieved 2015-07-15.
91.84 (in percent field for row with investor value "Individual")
- ^ Staff (June 15, 2015). "Products & Services". News. Genetic Engineering & Biotechnology News. Vol. 35, no. 12. p. 8.
Notes
- ^ "Jeong-sun Seo" in one news citation.